![ipos 4 gene ipos 4 gene](https://medcitynews.com/uploads/2016/12/GettyImages-479562442.jpg)
Italian Phase 1/2 biotech developing stem cell gene therapies for solid tumors. Seventh blank check company formed by Cantor Fitzgerald.īlank check company formed by Investcorp targeting businesses in Europe.īlank check company targeting the decarbonization and renewable energy sectors.īlank check company targeting mobility-related technology businesses.īlank check company led by SPAC veteran Betsy Cohen targeting sustainable businesses.īlank check company backed by Ault Global targeting disruptive technology.īlank check company formed by Ahren Innovation Capital targeting deep science and deep tech.īlank check company targeting electrification transition.īlank check company led by NXCR executives targeting the mobility-related ecosystem.īlank check company targeting businesses with a connection to the Asian market.īlank check company targeting global consumer-focused industries.īlank check company led by the founders of Revelstone Capital.īlank check company formed by IVEST Consumer Partners targeting disruptive consumer businesses.ĭevelops fleet management and other Internet of Things solutions for businesses. Provides satellite and space services and defense manufacturing.Īustralian Phase 2 biotech developing allosteric ion channel modulators for CNS disorders.īlank check company led by the founder of Kairous Capital targeting businesses in Asia. 20 IPOs During the Week of December 13th, 2021 Sidus Space finished up 133%.ġ4 SPACs went public led by electrification-focused Battery Future Acquisition ( BFAC.U) and Investcorp’s Investcorp Europe Acquisition I ( IVCBU), which both raised $300 million. Sidus Space has generated space-related manufacturing revenues to date, but is highly unprofitable with negative gross margin in the 9mo21. This company provides commercial satellite services such as design, manufacture, launch, and data collection. Micro-cap satellite developer Sidus Space ( SIDU) priced at the midpoint to raise $15 million at an $81 million market cap.
![ipos 4 gene ipos 4 gene](https://kaloramainformation.com/wp-content/uploads/sites/5/2021/09/cellgenescreenshot-300x186.png)
Ipos 4 gene trial#
Bionomics’ lead candidate, BNC210, is expected to begin its Phase 2 PREVAIL trial for social anxiety disorder by the end of 2021, with topline data anticipated by the end of 2022, and has already started its Phase 2b ATTUNE trial for PTSD, with topline data anticipated in the 1H23. Immix finished down 20%.Īustralia-listed Bionomics ( BNOX) raised $20 million at an $89 million market cap. Its lead candidate, IMX-110, is currently in Phase 1b/2a trials for solid tumors in the US and Australia. Immix Biopharma is developing a novel class of tissue-specific therapies in oncology and inflammation. Micro-cap Immix Biopharma ( IMMX) priced at the low end to raise $21 million at a $71 million market cap. Growing but highly unprofitable, Fresh Vine sells its wines through wholesale, retail, and DTC channels, and is able to conduct wholesale distribution in all 50 states and Puerto Rico. This celebrity-founded company produces low carb, low calorie premium wines. Wine brand Fresh Vine Wine ( VINE) priced at the high end to raise $22 million at a $122 million market cap.
![ipos 4 gene ipos 4 gene](https://slidetodoc.com/presentation_image/5f2f51b1eb53eee52b58696513f0c90c/image-8.jpg)
The company anticipates completing patient enrollment and treatment by the 2Q22. Genenta’s lead candidate, Temferon, is currently in a Phase 1/2a dose-escalation trial in newly diagnosed glioblastoma multiforme patients with unmethylated MGMT gene promoters. Italian solid tumor biotech Genenta Science ( GNTA) upsized and priced at the midpoint to raise $36 million at a $208 million market cap.